NEA Management Company’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-3,685,683
| Closed | -$15.5M | – | 53 |
|
|
2023
Q1 | $15.5M | Hold |
3,685,683
| – | – | 1.07% | 24 |
|
|
2022
Q4 | $22.2M | Hold |
3,685,683
| – | – | 1.24% | 21 |
|
|
2022
Q3 | $21.5M | Sell |
3,685,683
-4,361,545
| -54% | -$27.2M | 1.07% | 26 |
|
|
2022
Q2 | $48M | Buy |
8,047,228
+906,778
| +13% | +$4.64M | 2.47% | 10 |
|
|
2022
Q1 | $99.8M | Hold |
7,140,450
| – | – | 2.88% | 8 |
|
|
2021
Q4 | $17.7M | Hold |
7,140,450
| – | – | 0.36% | 34 |
|
|
2021
Q3 | $21.1M | Hold |
7,140,450
| – | – | 0.25% | 35 |
|
|
2021
Q2 | $17.9M | Hold |
7,140,450
| – | – | 0.23% | 44 |
|
|
2021
Q1 | $20.8M | Hold |
7,140,450
| – | – | 0.47% | 39 |
|
|
2020
Q4 | $23M | Hold |
7,140,450
| – | – | 0.61% | 31 |
|
|
2020
Q3 | $15.4M | Hold |
7,140,450
| – | – | 0.65% | 32 |
|
|
2020
Q2 | $8.28M | Hold |
7,140,450
| – | – | 0.33% | 35 |
|
|
2020
Q1 | $6.57M | Buy |
7,140,450
+3,390,450
| +90% | +$3.89M | 0.34% | 36 |
|
|
2019
Q4 | $5.83M | Hold |
3,750,000
| – | – | 0.28% | 38 |
|
|
2019
Q3 | $3.14M | Hold |
3,750,000
| – | – | 0.26% | 38 |
|
|
2019
Q2 | $3.22M | Hold |
3,750,000
| – | – | 0.23% | 36 |
|
|
2019
Q1 | $3.64M | Hold |
3,750,000
| – | – | 0.19% | 39 |
|
|
2018
Q4 | $2.74M | Hold |
3,750,000
| – | – | 0.11% | 39 |
|
|
2018
Q3 | $8.1M | Hold |
3,750,000
| – | – | 0.35% | 35 |
|
|
2018
Q2 | $18.7M | Hold |
3,750,000
| – | – | 0.87% | 23 |
|
|
2018
Q1 | $14.6M | Buy |
+3,750,000
| New | +$13.2M | 0.65% | 25 |
|
Other funds holding CTIC
NEA Management Company's CTIC Position: Q2 2023 in Review
NEA Management Company sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 3,685,683 shares — an estimated $15.5M sold.
NEA Management Company first reported a position in CTIC in Q1 2018 and held it in 21 quarters. The position peaked at $99.8M in Q1 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- NEA Management Company reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- NEA Management Company sold 3,685,683 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $15.5M.
- NEA Management Company first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2018 and held it in 21 quarters.
- NEA Management Company's CTI BioPharma Corp. (DE) Common Stock position peaked at $99.8M in Q1 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on NEA Management Company's 13F filing for Q2 2023, filed 11 Aug 2023.